3 recruiting, 2 completed, 1 unknown. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Recruiting 3, Completed 2, Unknown 1 |
Follow ST-Segment Elevation Myocardial Infarction (STEMI): new trials by email Literature Review of ST-Segment Elevation Myocardial Infarction (STEMI) trials Research Report on ST-Segment Elevation Myocardial Infarction (STEMI)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention Adenosine pre-medication, Standard care - ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon | Phase 4 | Recruiting | National Institute of Cardiovascular Diseases, Pakistan | 1148 | 2025-06-01 | 2026-04-22 |
| Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden rhTNK-tPA, 4-8 mg, Tirofiban - ST-segment Elevation Myocardial Infarction (STEMI) | Phase 4 | Recruiting | Henan Institute of Cardiovascular Epidemiology | 300 | 2025-01-01 | 2026-05-22 |
| PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction No aspirin (Prasugurel monotherapy), 12-month DAPT - ST-segment Elevation Myocardial Infarction (STEMI) | Phase 4 | Recruiting | Kindai University | 2258 | 2023-02-28 | 2023-03-01 |
| The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI Ketotifen Fumarate, standard treatment - ST-segment Elevation Myocardial Infarction (STEMI) | Phase 4 | Unknown | Peking University Third Hospital | 60 | 2022-09-01 | 2022-08-23 |
| Prolonged Clinical Follow-up of OPTIMA-5 Recombinant Staphylokinase, Normal Saline - ST-segment Elevation Myocardial Infarction (STEMI) | Phase 4 | Completed | The First Affiliated Hospital with Nanjing Medical University | 210 | 2021-10-29 | 2024-09-25 |
| The Effect of IV Cangrelor and Oral Ticagrelor Study Cangrelor, Ticagrelor - Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR) | Phase 4 | Completed | The Royal Wolverhampton Hospitals NHS Trust | 100 | 2016-07-21 | 2025-05-02 |
ST Elevation Myocardial Infarction (6) · Acute Coronary Syndrome (2) · Angina, Unstable (1) · Myocardial Infarction (1) · No-Reflow Phenomenon (1)
Cardiovascular Diseases (6) · Heart Diseases (6) · Infarction (6) · Ischemia (6) · Myocardial Ischemia (6) · Necrosis (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Vascular Diseases (6) · Myocardial Infarction (5) · Angina Pectoris (1) · Chest Pain (1) · Neurologic Manifestations (1) · Pain (1) · Signs and Symptoms (1)
2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine (1) · Ketotifen (1) · N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester (1) · Saline Solution (1) · Standard of Care (1) · Ticagrelor (1) · Tirofiban (1) · cangrelor (1)
Henan Institute of Cardiovascular Epidemiology (1) · Kindai University (1) · National Institute of Cardiovascular Diseases, Pakistan (1) · Peking University Third Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1) · The Royal Wolverhampton Hospitals NHS Trust (1)
China (2) · Japan (1) · Pakistan (1) · United Kingdom (1)
Gaku Nakazawa, MD, PhD (1) · James Cotton (1) · Ming Cui, Doctor (1) · Muhammad Nauman, FCPS (1)